Memorial Sloan Kettering Cancer Center

Oric Pharmaceuticals, Inc.

Minna Delarae Balbas

Julio Cesar Medina

Lawrence R McGee

Xiaohui Du

Daqing Sun

Charles L Sawyers

Liusheng Zhu

Xuelei Yan

Yosup Rew

John Eksterowicz

Valeria R Fantin

Haiying Zhou

Yang Shen

Geoffrey L Greene

Michael J Evans

David Hosfield

Philip A Watson

Lawrence R Mcgee

Philip Watson

The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.

Modulators of resistant androgen receptor

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.

Inhibitors of glucocorticoid receptor

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

The present invention encompasses the recognition that an F876L mutation of the androgen receptor (AR) gene confers resistance to the antiandrogens enzalutamide (MDV3100) and ARN-509 and is associated with incidence and/or risk of castration resistant prostate cancer (CRPC). The present invention also provides other AR polypeptide sequences associated with increased incidence and/or risk of CRPC. The present invention also provides screening methods for identification and/or characterization of novel AR polypeptide sequences associated with increased incidence and/or risk of CRPC via exposure to antiandrogens and for identification and/or characterization of agents to treat and/or reduce risk of CRPC by virtue of their effect on AR transcriptional activation.

Androgen receptor variants and methods for making and using

The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful in medicine, and particularly for treating any of a variety of diseases, disorders or conditions.

Growing community of inventors

San Francisco, CA, United States of America

Minna Delarae Balbas